Nyxoah S.A. (NYXH)
7.00
-0.65 (-8.50%)
At close: Mar 31, 2025, 11:05 AM
Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A.

Country | BE |
IPO Date | Apr 28, 2021 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 183 |
CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, BE | |
Website | https://www.nyxoah.com |
Stock Details
Ticker Symbol | NYXH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001857190 |
CUSIP Number | n/a |
ISIN Number | BE0974358906 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Olivier Taelman | Chief Executive Officer & Executive Director |
John Landry | Chief Financial Officer |
An Moonen | General Counsel |
Bruno Onkelinx | Chief Operations Officer |
Jeyakumar Subbaroyan | Chief Clinical Officer |
Loic Moreau | President of International |
Maggie McGowan | Chief HR Officer |
Mikaela Kirkwood | Corporate Communication & Investor Relations Manager |
Remi Renard | Chief of Staff |
Robert Taub MBA | Co-Founder & Chairman |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2025 | 6-K | Filing |
Mar 20, 2025 | F-3 | Filing |
Mar 20, 2025 | S-8 | Filing |
Mar 20, 2025 | 20-F | Filing |
Mar 13, 2025 | 6-K | Filing |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Jan 02, 2025 | 6-K | Filing |
Dec 13, 2024 | 6-K | Filing |
Dec 02, 2024 | 6-K | Filing |
Nov 20, 2024 | 6-K | Filing |